Article Details
Retrieved on: 2018-01-03 22:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Bristol-Myers Squibb and <b>New Enterprise Associates</b> (NEA) have co-led a $75 million investment in Personal Genome Diagnostics (PGDx). The series B gives PGDx the means to pursue approvals of its tissue and liquid biopsy IVD cancer tests in markets around the world. PGDx has rolled out a range of ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here